Trial reportOphthalmology2014
Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis.
Trial report in Ophthalmology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 65 citations in OpenAlex.
- Changing Azole Resistance: A Secondary Analysis of the MUTT I Randomized Clinical Trial.JAMA ophthalmology · 2016Trial
- Multidrug antifungal resistance and clinical outcomes in fungal keratitis: a prospective study in a South Indian population.Eye (London, England) · 2026Article
- Natural Product-Inspired Antifungal Drugs Introduced for Human Use from 1872 to August 2026.Antibiotics (Basel, Switzerland) · 2026Review
- Morphological Changes in Fungal Elements and Antifungal Drug Susceptibility in an Ex Vivo Model of Fungal Keratitis.Investigative ophthalmology & visual science · 2026Article
- Natamycin in Food and Ophthalmology: Knowledge Gaps and Emerging Insights from Zebrafish Models.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Pharmaco-Technological Characterization, Structural Analysis, and Toxicological Evaluation of the Novel Polyene Antibiotic Roseofungin for Drug Development.Pharmaceutics · 2025Article
- Antifungal susceptibility, clinical findings, and biofilm resistance of Fusarium species causing keratitis: a challenge for disease control.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- kexB Gene Correlates With Aspergillus flavus Keratitis Severity: A Whole-Genome Analysis.Investigative ophthalmology & visual science · 2025Article
- Association between in vitro susceptibility and clinical outcomes in fungal keratitis.Journal of ophthalmic inflammation and infection · 2024Article
- Pseudolaric acid B exerts an antifungal effect and targets SIRT1 to ameliorate inflammation by regulating Nrf2/NF-κB pathways in fungal keratitis.Inflammopharmacology · 2024Article
- Impression Cytologic Evaluation of the Conjunctiva in Patients Treated with Topical 1% VoriconazoleTurkish journal of ophthalmology · 2024Article
- Antifungal susceptibility profiles for fungal isolates from corneas and contact lenses in the United Kingdom.Eye (London, England) · 2024Article
- The mammalian Ire1 inhibitor, 4µ8C, exhibits broad anti-Frontiers in cellular and infection microbiology · 2024Article
- Antifungal Efficacy of Luliconazole in an Experimental Rabbit Model of Fungal Keratitis Caused by Fusarium solani.Mycopathologia · 2023Article
- Rapid Point-of-Care Identification of Aspergillus Species in Microbial Keratitis.JAMA ophthalmology · 2023Article
- Molecular epidemiology of clinical filamentous fungi in Qatar beyond Aspergillus and Fusarium with notes on the rare species.Medical mycology · 2022Article
- Multicenter prospective observational study of fungal keratitis in Japan: analyses of culture-positive cases.Japanese journal of ophthalmology · 2022Observational
- Multicenter prospective observational study of fungal keratitis in Japan: analyses of in vitro susceptibility tests for combinations of drugs.Japanese journal of ophthalmology · 2022Observational
- Diagnosing Fungal Keratitis and Simultaneously IdentifyingJournal of fungi (Basel, Switzerland) · 2022Article
- Expression of immune response genes in human corneal epithelial cells interacting with Aspergillus flavus conidia.BMC genomics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
Abstract
purposeTo assess the association between minimum inhibitory concentration (MIC) and clinical outcomes in a fungal keratitis clinical trial.
designExperimental study using data from a randomized comparative trial.
participantsOf the 323 patients enrolled in the trial, we were able to obtain MIC values from 221 patients with monocular fungal keratitis.
methodsThe Mycotic Ulcer Treatment Trial I was a randomized, double-masked clinical trial comparing clinical outcomes of monotherapy with topical natamycin versus voriconazole for the treatment of fungal keratitis. Speciation and determination of MIC to natamycin and voriconazole were performed according to Clinical and Laboratory Standards Institute guidelines. The relationship between MIC and clinical outcome was assessed.
main outcome measuresThe primary outcome was 3-month best spectacle-corrected visual acuity. Secondary outcomes included 3-month infiltrate or scar size; corneal perforation and/or therapeutic penetrating keratoplasty; and time to re-epithelialization.
resultsA 2-fold increase in MIC was associated with a larger 3-month infiltrate or scar size (0.21 mm; 95% confidence interval [CI], 0.10-0.31; P < 0.001) and increased odds of perforation (odds ratio, 1.32; 95% CI, 1.04-1.69; P = 0.02). No correlation was found between MIC and 3-month visual acuity. For natamycin-treated cases, an association was found between higher natamycin MIC with larger 3-month infiltrate or scar size (0.29 mm; 95% CI, 0.15-0.43; P < 0.001) and increased perforations (odds ratio, 2.41; 95% CI, 1.46-3.97; P < 0.001). Among voriconazole-treated cases, the voriconazole MIC did not correlate with any of the measured outcomes in the study.
conclusionsDecreased susceptibility to natamycin was associated with increased infiltrate or scar size and increased odds of perforation. There was no association between susceptibility to voriconazole and outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.